Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Top 3 drug approvals in November 2021 – Fyarro™, Tagrisso® and Retsevmo

Written by Jade Parker, Senior Editor

Fyrarro drug approval

As we draw closer to the end of 2021, we are looking at what key drugs have been approved for cancer in November. Highlights from the past month include the approval of drugs by the USA FDA and NICE for rare diseases, addressing unmet needs and in turn, improving the prognosis for patients with the conditions. Fyarro™ (mobocertinib) Approved: 23 November 2021 Company: Aadi Bioscience, Inc. (CA, USA) Indication: Locally advanced-unresectable or metastatic-malignant perivascular-epithelioid cell tumor In November a small biopharmaceutical company received the stamp of approval from the FDA, resulting in its shares skyrocketing by 25%. Mobocertinib is the first...

To view this content, please register now for access

It's completely free